Immune globulin intravenous (human), 10% liquid - Biologic Drug Details

Summary for immune globulin intravenous (human), 10% liquid

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for immune globulin intravenous (human), 10% liquid

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for immune globulin intravenous (human), 10% liquid Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for immune globulin intravenous (human), 10% liquid Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for immune globulin intravenous (human), 10% liquid Derived from Patent Text Search

No patents found based on company disclosures

Immune globulin intravenous (human), 10% liquid Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Intravenous Immunoglobulin (IVIG)

Market Size and Growth Projections

The intravenous immunoglobulin (IVIG) market is experiencing significant growth, driven by several key factors. As of 2023, the global IVIG market size was valued at approximately USD 12.7 billion and is projected to reach USD 23.5 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 5.76% during the period from 2024 to 2034[1].

Another projection estimates the market to reach around USD 34.92 billion by 2034, with a CAGR of 8.1% from 2024 to 2034, highlighting the robust expansion of this market[3].

Key Drivers of Market Growth

Increasing Prevalence of Autoimmune and Inflammatory Diseases

The rising instances of immune and autoimmune diseases such as Kawasaki disease, dermatomyositis, and polymyositis are major drivers of the IVIG market. These conditions necessitate the use of IVIG as a treatment option, thereby increasing demand[3].

Advancements in Production Technologies

Technological advancements in plasma fractionation and purification processes have improved the quality and consistency of IVIG products. These advancements address previous supply constraints and enhance the safety and efficacy of IVIG treatments[1].

Heightened Awareness and Early Diagnosis

Increased awareness about IVIG therapies and early diagnosis of immunodeficiency and autoimmune diseases have contributed to the growing demand for IVIG treatments. This heightened awareness is particularly significant in regions with well-structured healthcare systems[4].

Geographical Market Distribution

North America

North America, particularly the United States, holds a significant share of the IVIG market. The region's developed healthcare system, growing focus on research and development, and the strong presence of market players are key factors driving this dominance. The United States has the largest patient pool for IVIG and represents the biggest market for its treatment[1][4].

Europe and Other Regions

Countries like Germany, France, the United Kingdom, Italy, and Spain also constitute major markets for IVIG. Japan is another significant market, driven by similar factors such as the prevalence of autoimmune diseases and advancements in medical biotechnology[1].

Product and Application Segments

Product Types

The IVIG market is dominated by IgG products, which are the most commonly used type of immunoglobulin for treating various immunodeficiencies and autoimmune diseases[3].

Applications

IVIG is used to treat a range of conditions, including immunodeficiency diseases, autoimmune diseases, infections, and inflammatory conditions. The immunodeficiency diseases segment captured more than 21% of the revenue share in 2023, indicating its significant contribution to the market[3].

End-User and Distribution Channels

End-Users

Hospitals are the primary end-users of IVIG, with this segment expected to share the maximum CAGR during the projection period. The use of IVIG in hospital settings is driven by the need for controlled and monitored administration of the therapy[3].

Distribution Channels

Hospital pharmacies contribute significantly to the revenue share of the IVIG market, with over 58% of the revenue share in 2023. This highlights the importance of hospital-based distribution channels in ensuring accessibility and affordability of IVIG treatments[3].

Financial Aspects and Cost Considerations

Cost of IVIG Treatment

The cost of IVIG treatment is relatively high, with a single infusion costing anywhere from $100 to over $350 per gram. On average, the reported cost for IVIG treatment in the US is approximately $9,720, and for patients undergoing 4 to 5 infusions per month, the cost can be around $41,796 per month[2].

Strategies to Manage Costs

Given the high costs, strategies to manage expenses associated with IVIG infusion are crucial. These include understanding the cost factors, exploring financial assistance programs, and optimizing treatment protocols to minimize costs without compromising efficacy[2].

Regulatory Approvals and Innovations

Recent Approvals

In January 2024, the FDA approved Hyqvia, a combination of immune globulin infusion 10% with recombinant human hyaluronidase, as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This approval highlights the ongoing innovation in IVIG therapies and their expanding applications[1].

Technological Innovations

Medical advances in treating patients with primary prevention, along with significant industry innovations such as immune system clearance and enhancement, have improved the performance and safety of immunoglobulin therapies. These innovations reduce adverse events and improve patient outcomes, further driving market growth[3].

Challenges and Adverse Effects

High Costs and Complex Production Processes

Despite the growth, the IVIG market faces challenges such as high production costs and complex production processes. These factors can impact the affordability and accessibility of IVIG treatments[3].

Adverse Effects

IVIG therapy, while effective, can have adverse effects such as thrombotic events, particularly in patients with risk factors like advanced age, prior thrombosis, and hypercoagulable states. Early assessment and anti-thrombus treatment are essential in managing these risks[5].

Market Trends and Future Outlook

Personalized Medicine

The market is evolving towards personalized medicine, with IVIG being used in novel immunomodulatory treatments. This trend promises to further propel the market by offering tailored treatment options for patients[4].

Expansion of Distribution Channels

The expansion of distribution channels, including hospital and specialty pharmacies, contributes significantly to the growth of the IVIG market. This ensures better accessibility and affordability of IVIG treatments worldwide[4].

Key Takeaways

• The IVIG market is projected to grow significantly, driven by increasing prevalence of autoimmune diseases and advancements in production technologies.
• North America, particularly the United States, dominates the market due to its well-structured healthcare system and high prevalence of target diseases.
• The cost of IVIG treatment is high, but strategies to manage costs and recent regulatory approvals are enhancing accessibility and efficacy.
• The market is trending towards personalized medicine and expanded distribution channels, promising further growth.

Frequently Asked Questions (FAQs)

Q: What is the projected market size of the IVIG market by 2034? A: The IVIG market is expected to reach around USD 23.5 billion by 2034, with some projections estimating it could reach up to USD 34.92 billion[1][3].

Q: What are the main drivers of the IVIG market growth? A: The main drivers include the increasing prevalence of autoimmune and inflammatory diseases, advancements in production technologies, and heightened awareness about IVIG therapies[1][3].

Q: How expensive is IVIG treatment? A: The average cost for IVIG treatment in the US is approximately $9,720, and for patients undergoing 4 to 5 infusions per month, the cost can be around $41,796 per month[2].

Q: What are the common applications of IVIG? A: IVIG is used to treat various immunodeficiency diseases, autoimmune diseases, infections, and inflammatory conditions[3].

Q: What are the potential adverse effects of IVIG therapy? A: Potential adverse effects include thrombotic events, particularly in patients with risk factors such as advanced age, prior thrombosis, and hypercoagulable states[5].

Sources:

1. Biospace - Intravenous Immunoglobulin Market Size to Reach USD 23.5 Billion by 2034[1]
2. AmeriPharma Specialty Care - Cost of IVIG Treatment[2]
3. Biospace - Intravenous Immunoglobulin Market Experiencing Growth of 8.1% by 2034[3]
4. Mordor Intelligence - Intravenous Immunoglobulin Market - IVIG - Share, Trends & Growth[4]
5. Frontiers in Immunology - Adverse Effects of Immunoglobulin Therapy[5]